**10. Multi-targeted tyrosine kinase inhibitors**

Several anti-angiogenic small-molecule tyrosine kinase inhibitors (TKIs) are in current clini‐ cal development. An advantage of TKIs includes the fact that they inhibit multiple receptors simultaneously, with anti-angiogenic and anti-proliferative activity against NSCLC, thereby potentially providing a higher likelihood of single-agent activity. Another benefit is that these agents are often available orally, offering patients greater convenience. However, tox‐ icity remains a concern given the multi-targeted kinase inhibition and the additive adverse effects that may be of particular concern when the agents are combined with chemotherapy.
